Kamada (KMDA) - Total Liabilities
Based on the latest financial reports, Kamada (KMDA) has total liabilities worth ILA111.98 Million ILA (≈ $300.21K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kamada - Total Liabilities Trend (2006–2024)
This chart illustrates how Kamada's total liabilities have evolved over time, based on quarterly financial data. See Kamada working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Kamada Competitors by Total Liabilities
The table below lists competitors of Kamada ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GemVax&KAEL Co.Ltd
KQ:082270
|
Korea | ₩101.65 Billion |
|
Suzhou Mingzhi Technology Co. Ltd. A
SHG:688355
|
China | CN¥319.92 Million |
|
Bijou Brigitte modische Accessoires Aktiengesellschaft
XETRA:BIJ
|
Germany | €169.97 Million |
|
Mobiltel Iletisim Hizmetleri Sanayi ve Ticaret AS
IS:MOBTL
|
Turkey | TL3.83 Billion |
|
AMTD Digital Inc.
NYSE:HKD
|
USA | $351.62 Million |
|
BTS Group AB (publ)
ST:BTS-B
|
Sweden | Skr1.59 Billion |
|
Yem Chio Co Ltd
TW:4306
|
Taiwan | NT$24.02 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down Kamada's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see KMDA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kamada's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kamada (2006–2024)
The table below shows the annual total liabilities of Kamada from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA112.79 Million ≈ $302.39K |
+1.72% |
| 2023-12-31 | ILA110.89 Million ≈ $297.28K |
-24.24% |
| 2022-12-31 | ILA146.36 Million ≈ $392.38K |
+3.18% |
| 2021-12-31 | ILA141.84 Million ≈ $380.28K |
+342.89% |
| 2020-12-31 | ILA32.03 Million ≈ $85.86K |
-16.77% |
| 2019-12-31 | ILA38.48 Million ≈ $103.16K |
+49.49% |
| 2018-12-31 | ILA25.74 Million ≈ $69.01K |
-21.09% |
| 2017-12-31 | ILA32.62 Million ≈ $87.45K |
-1.02% |
| 2016-12-31 | ILA32.95 Million ≈ $88.35K |
+11.76% |
| 2015-12-31 | ILA29.48 Million ≈ $79.05K |
-23.66% |
| 2014-12-31 | ILA38.62 Million ≈ $103.55K |
-21.83% |
| 2013-12-31 | ILA49.41 Million ≈ $132.46K |
-18.63% |
| 2012-12-31 | ILA60.72 Million ≈ $162.79K |
-3.27% |
| 2011-12-31 | ILA62.78 Million ≈ $168.30K |
-3.47% |
| 2010-12-31 | ILA65.03 Million ≈ $174.36K |
+98.51% |
| 2009-12-31 | ILA32.76 Million ≈ $87.83K |
+11.36% |
| 2008-12-31 | ILA29.42 Million ≈ $78.87K |
-48.56% |
| 2007-12-31 | ILA57.19 Million ≈ $153.32K |
+33.60% |
| 2006-12-31 | ILA42.80 Million ≈ $114.76K |
-- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more